Center for Predictive Medicine – Mission
The mission of the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM) is to improve human health by conducting basic and translational research that leads to the development of effective diagnostic biomarkers, vaccines, antivirals and therapeutics for emerging, re-emerging, neglected or rare infectious diseases.
Research that leads to effective translation is necessarily multidisciplinary, and hence, the Center comprises faculty from the Departments of Microbiology and Immunology, Pharmacology and Toxicology, and Radiology. Molecular imaging of host and pathogen responses during infection is a critical cornerstone of the Center. Imaging methods that visualize the structure and function of the living body are widely used in clinical and biomedical research settings. The full potential of these methods has not been fully realized in regards to the study and treatment of the diseases caused by infectious agents. Importantly, the molecular imaging models that are developed can be employed to accelerate the discovery of targets and drugs for therapeutic intervention, and biomarkers that could be used for early diagnosis.
In addition to the research activities led by the faculty within the CPM, the National Institutes of Health (NIH) collaborated with the University of Louisville (UofL) to construct and commission the UofL Regional Biocontainment Laboratory (RBL). This state-of-the-art facility managed and operated as a Shared Resource by the CPM, provides the greater community and nation with scientific expertise and biosafety level three (BSL-3) laboratories for the discovery of therapeutics for serious pathogens, and an infrastructure to meet pandemic or bioterrorism emergency needs. The RBL, one of 11 in the country, serves as a valuable shared resource to others in academic, not-for-profit and private sectors for BSL-3 training, basic research and translational discovery efforts.